CP60.F The Cooper Companies, Inc.
- Market cap
- EUR 10.9B
- P/E
- 22.9x
- P/B
- 1.45x
- ROE
- 7.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.
Is CP60.F undervalued?
Graham numberCP60.F trades 21.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
The Cooper Companies, Inc. fundamental analysis
No fundamental analysis for The Cooper Companies, Inc. yet.
The Cooper Companies, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About The Cooper Companies, Inc.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices…
Full company profileThe Cooper Companies, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
The Cooper Companies, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 2.43B | 2.92B | 3.31B | 3.59B | 3.90B | 4.09B | 4.23B |
| Gross Profit | 1.53B | 1.96B | 2.14B | 2.36B | 2.60B | 2.68B | 2.86B |
| Operating Income | 312M | 506M | 508M | 533M | 706M | 683M | 538M |
| EBITDA | - | - | 879M | 886M | 1.07B | 1.04B | 928M |
| Net Income | 238M | 2.94B | 386M | 294M | 392M | 375M | 648M |
| EPS | 1.21 | 15 | 1.96 | 1.49 | 1.97 | 1.91 | 3.41 |
| Balance Sheet | |||||||
| Total Assets | 6.74B | 9.61B | 11.5B | 11.7B | 12.3B | 12.4B | 12.7B |
| Total Liabilities | 2.91B | 2.66B | 4.32B | 4.11B | 4.23B | 4.16B | 4.35B |
| Shareholders' Equity | 3.82B | 6.94B | 7.17B | 7.55B | 8.08B | 8.24B | 8.33B |
| Cash & Short-term Investments | 116M | 95.9M | 138M | 121M | 108M | 111M | 155M |
| Cash Flow | |||||||
| Operating Cash Flow | 487M | 739M | 692M | 608M | 709M | 796M | 1.05B |
| Capital Expenditure | 310M | 214M | 242M | 393M | 421M | 362M | 343M |
| Free Cash Flow | 176M | 524M | 450M | 215M | 288M | 434M | 704M |
| Ratios | |||||||
| ROE | 6.2% | 42.4% | 5.4% | 3.9% | 4.9% | 4.6% | 7.8% |
| ROA | 3.5% | 30.7% | 3.4% | 2.5% | 3.2% | 3.0% | 5.1% |
| Net Profit Margin | 9.8% | 100.8% | 11.7% | 8.2% | 10.1% | 9.2% | 15.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
The Cooper Companies, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 26, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 3.00M | 0.02 | 1.0% |
| 2022 | USD 3.00M | 0.02 | 0.8% |
| 2021 | USD 3.00M | 0.02 | 0.1% |
| 2020 | USD 3.00M | 0.02 | 1.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Feb 20, 2024.
Who owns The Cooper Companies, Inc.
- Insiders 0.63%
- Institutions 99.37%
- Public & others 0.00%
- Shares outstanding 190M
- Free float 189M
The Cooper Companies, Inc. company profile
- Company name
- The Cooper Companies, Inc.
- Ticker
- CP60.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Employees
- 15,000
- Fiscal year end
- October
- Address
- 6101 Bollinger Canyon Road, San Ramon, CA, United States, 94583
- Phone
- 925 460 3600
- Website
- coopercos.com
About The Cooper Companies, Inc.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
The Cooper Companies, Inc. management
7- Mr. Brian G. AndrewsExecutive VP, CFO & Principal Accounting Officer · born 1979
- Mr. Daniel G. McBride Esq.Executive VP, COO General Counsel & Secretary · born 1964
- Mr. Albert G. White IIIStrategic Advisor · born 1970
- Ms. Holly R. SheffieldPresident of CooperSurgical, Inc. · born 1971
- Mr. Gerard H. Warner IIIPresident of CooperVision, Inc. · born 1965
- Mr. Walter M. Rosebrough Jr.Interim Executive Chair · born 1954
- Mr. Kim DuncanVice President of Investor Relations & Risk Management